scholarly journals DOCKING KURKUMIN DAN SENYAWA ANALOGNYA PADA RESEPTOR PROGESTERON: STUDI INTERAKSINYA SEBAGAI Selective Progesterone Receptor Modulators (SPRMs)

2012 ◽  
Vol 13 (2) ◽  
pp. 55-60
Author(s):  
Edy Meiyanto

Kurkumin merupakan suatu kandungan dari Curcuma longa L.,yang telah dibuktikan efek sitotoksiknya secara in vitro terhadap sel kanker payudara. Senyawa analog kurkumin: PGV-0, PGV-1, HGV-0, dan HGV-1, hasil modifikasi dari kurkumin, diperkirakan memiliki aksi yang sama. Penelitian ini bertujuan untuk mengetahui afinitas dan interaksi dari kurkumin dan analognya sebagai Selective Progesterone Receptor Modulators (SPRMs) dalam mengadakan inhibisi kompetitif dengan hormon progesteron. Optimasi geometri struktur kurkumin dan analognya dilakukan dengan software Hyperchem 7.5. Konformasi optimum PGV-0 dan PGV-1 dihasilkan melalui metode AM1 sedangkan kurkumin, HGV-0, dan HGV-1 dengan metode PM3. Kemudian dilakukan proses docking senyawa uji dengan bindingsite hormon progesteron pada reseptor progesteron (IA28) menggunakan software Arguslab 4.01, dalam kondisi ada dan tanpa air. Proses ini dilakukan dengan metode GAdock. Dari proses docking diperoleh nilai (Gibbs free energy)DG terendah pada senyawa kurkumin bentuk keto baik dengan maupun tanpa air. Afinitas terbesar turunan kurkumin ditunjukkan oleh PGV-1 pada keadaan ada air dan  HGV-1 tanpa air pada reseptor progesteron. 'font-family: "Arial","sans-serif";mso-ansi-language:IN'Kata kunci: kurkumin dan analognya, SPRMs, docking, reseptor  progesteron IA28 -language:IN'Antiradikal, DPPH, IC50, fenolik total, Elephantopus schaber L., Ocimum basilicum L.forma citratum Back., Graptophylum pictum Griff, Gynura procumbens Merr. 

2020 ◽  
Vol 41 (5) ◽  
pp. 643-694 ◽  
Author(s):  
Md Soriful Islam ◽  
Sadia Afrin ◽  
Sara Isabel Jones ◽  
James Segars

Abstract Selective progesterone receptor modulators (SPRMs) are a new class of compounds developed to target the progesterone receptor (PR) with a mix of agonist and antagonist properties. These compounds have been introduced for the treatment of several gynecological conditions based on the critical role of progesterone in reproduction and reproductive tissues. In patients with uterine fibroids, mifepristone and ulipristal acetate have consistently demonstrated efficacy, and vilaprisan is currently under investigation, while studies of asoprisnil and telapristone were halted for safety concerns. Mifepristone demonstrated utility for the management of endometriosis, while data are limited regarding the efficacy of asoprisnil, ulipristal acetate, telapristone, and vilaprisan for this condition. Currently, none of the SPRMs have shown therapeutic success in treating endometrial cancer. Multiple SPRMs have been assessed for efficacy in treating PR-positive recurrent breast cancer, with in vivo studies suggesting a benefit of mifepristone, and multiple in vitro models suggesting the efficacy of ulipristal acetate and telapristone. Mifepristone, ulipristal acetate, vilaprisan, and asoprisnil effectively treated heavy menstrual bleeding (HBM) in patients with uterine fibroids, but limited data exist regarding the efficacy of SPRMs for HMB outside this context. A notable class effect of SPRMs are benign, PR modulator-associated endometrial changes (PAECs) due to the actions of the compounds on the endometrium. Both mifepristone and ulipristal acetate are effective for emergency contraception, and mifepristone was approved by the US Food and Drug Administration (FDA) in 2012 for the treatment of Cushing’s syndrome due to its additional antiglucocorticoid effect. Based on current evidence, SPRMs show considerable promise for treatment of several gynecologic conditions.


Sign in / Sign up

Export Citation Format

Share Document